Arcutis Biotherapeutics Welcomes Max Homa to 'Free to Be Me' Campaign for Seborrheic Dermatitis Awareness

On February 24, 2026, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced an exciting partnership with professional golfer Max Homa, who has joined the company’s *Free to Be Me* awareness campaign. This initiative aims to raise awareness about seborrheic dermatitis (seb derm), a chronic skin condition affecting millions of Americans. Homa, a six-time PGA Tour winner, shares his personal journey and encourages others suffering from seb derm to engage in conversations with healthcare providers regarding long-term treatment options.

Homa's struggle with seb derm resonates with many. He spent years grappling with self-diagnosis and ineffective over-the-counter treatments, which left him feeling frustrated and uncertain. “Even on the days when my face wasn’t red or flaky, seb derm was in the back of my mind,” Homa stated. His breakthrough came with a proper diagnosis and effective treatment using ZORYVE, a topical foam developed by Arcutis. “Getting a proper diagnosis and treating my seb derm with ZORYVE made a big difference,” he emphasized, highlighting how targeted treatment allowed him to focus on what truly matters in life.

Seborrheic dermatitis is characterized by persistent flaking, redness, and itching, significantly impacting individuals' quality of life. Dr. Tina Bhutani, a board-certified dermatologist and CEO of Synergy Dermatology, noted the emotional toll of this skin condition. Many patients often misinterpret the symptoms as mere dandruff, leading to a delay in seeking appropriate medical help. Dr. Bhutani advocates for effective, well-tolerated treatments such as ZORYVE, which is designed for long-term use.

ZORYVE foam 0.3% is indicated for the treatment of seborrheic dermatitis in both adults and children aged nine and older. This innovative formulation is a water-based foam that is free of sensitizers or irritants, making it suitable for all skin and hair types. Clinical trials have shown promising results: 77% of participants achieved clear or almost clear skin after eight weeks of using ZORYVE, compared to just 53% in the control group. Notably, nearly 63% of those using ZORYVE reported significant itch relief within eight weeks.

ZORYVE foam has been well-tolerated in clinical studies, with the most common side effects being nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%). These adverse reactions were consistent over long-term studies lasting up to a year, indicating a favorable safety profile.

ZORYVE has garnered several prestigious awards in the dermatological field. It was awarded the "2025 Best of Beauty Breakthrough Award" by *Allure*, making it the first FDA-approved medication to win such an accolade for treating multiple inflammatory dermatoses. Additionally, it has received the National Psoriasis Foundation’s Seal of Recognition and was honored in 2024 with *Glamour’s* Beauty and Wellness Award for “Best Eczema Product.”

The *Free to Be Me* campaign is dedicated to sharing real experiences of individuals battling inflammatory skin conditions, including seb derm. By sharing these stories, Arcutis aims to empower others to initiate conversations with healthcare providers and explore effective treatment plans.

With Max Homa as a spokesperson, Arcutis Biotherapeutics is poised to enhance awareness and understanding of seborrheic dermatitis through the *Free to Be Me* campaign. By advocating for open dialogue about skin conditions and promoting innovative treatments like ZORYVE, Arcutis continues to lead the charge in addressing the needs of individuals living with immune-mediated dermatological diseases.